Research indicates that AAT levels are reduced in metabolic syndrome-related diseases such as T2DM, ischemic stroke, and non-alcoholic fatty liver disease (20). This evidence concerns the gene SERPINA1 and metabolic dysfunction-associated steatotic liver disease.